Delineation of biological and molecular mechanisms underlying the diverse anticancer activities of mycophenolic acid

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 12, 2013, Pages 2880-2886

  Dun, Boying ^a,b,c   Xu, Heng ^b,c   Sharma, Ashok ^b   Liu, Haitao ^b   Yu, Hongfang ^b   Yi, Bing ^b   Liu, Xiaoxin ^c   He, Mingfang ^c   Zeng, Lingwen ^a   She, Jin Xiong ^b,c  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c NANJING TECH UNIVERSITY   (China)

Author keywords

Apoptosis; Cancer; Drug repurposing; Mpa; Xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; MTOR PROTEIN, HUMAN; MYCOPHENOLIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TARGET OF RAPAMYCIN KINASE;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECT; DRUG REPOSITIONING; DRUG RESISTANCE; DRUG SCREENING; HEPG2 CELL LINE; HUMAN; IC 50; MALE; MCF 7 CELL LINE; METABOLISM; MOUSE; MPA; NEOPLASM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TIME; TUMOR VOLUME; XENOGRAFT;

APOPTOSIS; CANCER; DRUG REPURPOSING; MPA; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HEP G2 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; MYCOPHENOLIC ACID; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TIME FACTORS; TOR SERINE-THREONINE KINASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84888811354     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Millan O, Oppenheimer F, Brunet M, Vilardell J, Rojo I, Vives J and Martorell J. Assessment of mycophenolic acid-induced immunosuppression: a new approach. Clin Chem 2000; 46: 1376-1383.
2. Allison AC and Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005; 80: S181-190.
3. Morath C, Schwenger V, Beimler J, Mehrabi A, Schmidt J, Zeier M and Muranyi W. Antifibrotic actions of mycophenolic acid. Clinical Transplantation 2006; 20 Suppl 17: 25-29.
4. Allison AC and Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
5. Jackson RC, Weber G and Morris HP. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 1975; 256: 331-333.
6. Kozhevnikova EN, van der Knaap JA, Pindyurin AV, Ozgur Z, van Ijcken WF, Moshkin YM and Verrijzer CP. Metabolic enzyme IMPDH is also a transcription factor regulated by cellular state. Mol Cell 2012; 47: 133-139.
7. Fellenberg J, Bernd L, Delling G, Witte D and Zahlten-Hinguranage A. Prognostic significance of drug-regulated genes in high-grade osteosarcoma. Mod Pathol 2007; 20: 1085-1094.
8. Fellenberg J, Kunz P, Sahr H and Depeweg D. Overexpression of inosine 5'-monophosphate dehydrogenase type II mediates chemoresistance to human osteosarcoma cells. PLoS One 2010; 5: e12179.
9. Takebe N, Cheng X, Fandy TE, Srivastava RK, Wu S, Shankar S, Bauer K, Shaughnessy J and Tricot G. IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells. Mol Cancer Ther 2006; 5: 457-466.
10. Gortz A, Franklin TJ, Dive C and Hickman JA. Cell cycle specific induction of HL-60 cell differentiation and apoptosis by mycophenolic acid. Cell Death Differ 1997; 4: 787-795.
11. Vegso G, Sebestyen A, Paku S, Barna G, Hajdu M, Toth M, Jaray J and Kopper L. Antiproliferative and apoptotic effects of mycophenolic acid in human B-cell non-Hodgkin lymphomas. Leuk Res 2007; 31: 1003-1008.
12. Silva SL, Silva SF, Cavalcante RO, Mota RS, Carvalho RA, Moraes MO, Campos HH and Moraes ME. Mycophenolate mofetil attenuates Walker's tumor growth when used alone, but the effect is lost when associated with cyclosporine. Transplant Proc 2004; 36: 1004-1006.
13. Domhan S, Muschal S, Schwager C, Morath C, Wirkner U, Ansorge W, Maercker C, Zeier M, Huber PE and Abdollahi A. Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther 2008; 7: 1656-1668.
14. Tressler RJ, Garvin LJ and Slate DL. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo. Int J Cancer 1994; 57: 568-573.
15. Sun XX, Dai MS and Lu H. Mycophenolic acid activation of p53 requires ribosomal proteins L5 and L11. J Biol Chem 2008; 283: 12387-12392.
16. Engl T, Makarevic J, Relja B, Natsheh I, Muller I, Beecken WD, Jonas D and Blaheta RA. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer 2005; 5: 4.
17. Wierstra I and Alves J. FOXM1, a typical proliferation-associated transcription factor. Biol Chem 2007; 388: 1257-1274.
18. Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A, Clevers H and Medema RH. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005; 7: 126-136.
19. Kim J, Goo SY, Chung HJ, Yang HW, Yong TS, Lee KH and Park SJ. Interaction of beta-giardin with the Bop1 protein in Giardia lamblia. Parasitol Res 2006; 98: 138-144.
20. Morgensztern D and McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005; 16: 797-803.
21. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS and Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Cur Opin Pharmacol 2008; 8: 393-412.
22. Cortot A, Armand JP and Soria JC. [PI3K-AKT-mTOR pathway inhibitors]. Bull Cancer 2006; 93: 19-26.
23. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM and Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999; 397: 441-446.